Our business model is to identify product opportunities in commercially and clinically relevant areas where our ElectroSpray technology and expertise can contribute to match or improve drug performance. We develop finished drug product formulations in support of ANDA and 505(b)(2) regulatory filings, secure product-specific intellectual property.